Trials / Completed
CompletedNCT01594996
European Drug Utilization Study
A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 814 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder. The study will also investigate how the medication is used for these patients and if there are any differences in drug utilisation between the included countries. The study is observing patients initiating Seroquel XR during a 9 month period corresponding to 3 to 12 months following the launch of the product in each country for the MDD indication. A drug utilisation questionnaire will be used to collect study data from patients' medical records.
Detailed description
A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU)
Conditions
Timeline
- Start date
- 2012-04-24
- Primary completion
- 2014-03-27
- Completion
- 2014-03-27
- First posted
- 2012-05-09
- Last updated
- 2017-11-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01594996. Inclusion in this directory is not an endorsement.